BAGGIO, BRUNO
 Distribuzione geografica
Continente #
NA - Nord America 9.481
EU - Europa 1.211
AS - Asia 979
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
SA - Sud America 2
Totale 11.682
Nazione #
US - Stati Uniti d'America 9.476
CN - Cina 449
SG - Singapore 398
FI - Finlandia 244
UA - Ucraina 244
DE - Germania 226
SE - Svezia 183
FR - Francia 127
VN - Vietnam 95
GB - Regno Unito 77
IT - Italia 77
HK - Hong Kong 22
IE - Irlanda 20
IN - India 11
NL - Olanda 6
EU - Europa 5
AU - Australia 4
CA - Canada 4
RS - Serbia 2
BR - Brasile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ES - Italia 1
ID - Indonesia 1
KH - Cambogia 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
TR - Turchia 1
Totale 11.682
Città #
Woodbridge 1.362
Fairfield 1.036
Jacksonville 913
Ann Arbor 907
Houston 861
Chandler 742
Ashburn 536
Wilmington 426
Princeton 358
Cambridge 351
Seattle 349
Singapore 322
Boardman 262
San Diego 100
Beijing 97
Nanjing 96
Des Moines 95
Dong Ket 94
Roxbury 89
Santa Clara 78
Medford 72
Helsinki 67
Hebei 37
Guangzhou 35
Norwalk 31
Nanchang 29
Jiaxing 24
Hong Kong 22
Shenyang 21
Dublin 20
Redwood City 15
Changsha 14
New York 12
Kharkiv 11
Tianjin 10
Jinan 9
London 9
Washington 8
Detroit 7
Borås 6
Greifswald 6
Los Angeles 6
Dallas 5
Ogden 5
Padova 5
Bologna 4
Milan 4
Tappahannock 4
Auburn Hills 3
Costa Mesa 3
Indiana 3
Kilburn 3
Lanzhou 3
Rockville 3
Rome 3
Zhengzhou 3
Casnate Con Bernate 2
Chengdu 2
Chicago 2
Chiswick 2
Delhi 2
Falls Church 2
Frankfurt am Main 2
Hefei 2
Islington 2
Kunming 2
Nürnberg 2
Orbassano 2
Pisa 2
Redmond 2
San Jose 2
Selargius 2
Shanghai 2
Sydney 2
Tolentino 2
Toronto 2
Viterbo 2
Wuhan 2
Acqui Terme 1
Acton 1
Atlanta 1
Belgrade 1
Brno 1
Camisano Vicentino 1
Camposampiero 1
Capurso 1
Caserta 1
Catford 1
Chongqing 1
Copenhagen 1
Coquitlam 1
Davao City 1
Dongguan 1
Eindhoven 1
Fazenda Rio Grande 1
Florence 1
Forest City 1
Genova 1
Girifalco 1
Greenwich 1
Totale 9.662
Nome #
DIFFERENT HEPARIN DOSAGES ARE NEEDED TO AMELIORATE THE EVOLUTION OF DIFFERENT EXPERIMENTAL NEPHROPATHIES - DOES THIS MEAN DIFFERENT HEPARIN TARGETS 134
An inheritable anomaly in red-cell oxalate transport in ''primary'' calcium nephrolithiasis correctable with diuretics. 128
Tyrosine-protein kinase inhibition in human erythrocytes by polyphosphoinositides (PIP and PIP2) 124
Functional correlation between the Ser/Thr-phosphorylation of band-3 and band-3-mediated transmembrane anion transport in human erythrocytes 123
Acquisizione del fenotipo miofibroblastico e transizione epItelio mesenchima in colture primarie di cellule renali umane. 122
Abnormal erythrocyte charge in diabetes mellitus: link with microalbuminuria. 121
In vivo activation of renal phospholipase activity by bradykinin in the rat. 121
VERY EARLY NUTRITION SUPPLEMENTATION IN BURNED PATIENTS 120
THERAPY WITH GLYCOSAMINOGLYCANS IN NEPHROLOGY 120
A critical evaluation of the urinary inhibiting activity in idiopathic calcium oxalate nephrolithiasis. 119
Relationship Between Membrane-protein Phosphorylation and Intracellular Translocation of Casein Kinase In Human Erythrocytes 118
ABNORMAL URATE TRANSPORT IN ERYTHROCYTES OF PATIENTS WITH IDIOPATHIC CALCIUM NEPHROLITHIASIS - A POSSIBLE LINK WITH HYPERURICOSURIA 114
Pathogenesis of idiopathic calcium nephrolithiasis: Update 1997 112
DIALYSIS-RELATED AMYLOIDOSIS 111
Further insights about the beneficial effects of n-3 fatty acids in the early molecular events of renal fibrosis in vitro. 110
ACE INHIBITORS IN RENAL-DISEASE 108
Patterns of renal injury in NIDDM patients with microalbuminuria 106
Digitalis and the renin-angiotensin axis in congestive heart failure. 106
Arachidonic acid-induced IL-6 expression is mediated by PKCalpha activation in osteoblastic cells 106
Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid 105
Renal impairment and moderate alcohol consumption in the elderly. Results from the Italian Longitudinal Study on Aging (ILSA). 104
Abnormal urate transport in erythrocytes of idiopathic calcium nephrolithiasis: a possible link with hyperuricosuria. 103
ANTIPROTEINURIC EFFECT OF GLYCOSAMINOGLYCANS 102
An inheritable anomaly of red-cell oxalate transport in "primary" calcium nephrolithiasis correctable with diuretics. 102
Genetic approach to the study of cellular ion transport anomalies in idiopathic calcium nephrolithiasis 101
EFFECTS OF THE ORAL-ADMINISTRATION OF GLYCOSAMINOGLYCANS ON CELLULAR ABNORMALITIES ASSOCIATED WITH IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS 100
EFFECT OF ALKALINE CITRATE THERAPY ON CLEARANCE OF RESIDUAL RENAL STONE FRAGMENTS AFTER EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY IN STERILE CALCIUM AND INFECTION NEPHROLITHIASIS PATIENTS 100
GLYCOSAMINOGLYCAN CONTENT, OXALATE SELF-EXCHANGE AND PROTEIN-PHOSPHORYLATION IN ERYTHROCYTES OF PATIENTS WITH IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS 98
Relation between band 3 red blood cell protein and transmembrane oxalate flux in stone formers. 98
Ischemic renal disease: impact of cardiovascular risk factors and smoking 97
Phosphorylation of Band-3 Protein In Nephrolithiasis 97
Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin 94
DIET AND NEPHROLITHIASIS - STUDY IN AN OBESE POPULATION 94
Glycosaminoglycans: A new paradigm in the prevention of proteinuria and progression of glomerular disease 93
CORRECTION OF ERYTHROCYTE ABNORMALITIES IN IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS AND REDUCTION OF URINARY OXALATE BY ORAL GLYCOSAMINOGLYCANS 93
Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis 92
Specific effect of arachidonic acid on inducible nitric oxide synthase mRNA expression in human osteoblastic cells 91
Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. 91
Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. 91
Kidney kallikrein and phospholipase activities in Milan spontaneously hypertensive rats. 90
Urinary angiotensin-I-converting enzyme activity as a marker of tubulo-interstitial involvement in kidney diseases. 89
A comparative kinetic RT/-PCR strategy for the quantitation of mRNAs in microdissected human renal biopsy specimens 89
ERYTHROCYTE URATE SELF EXCHANGE IN IDIOPATHIC CALCIUM NEPHROLITHIASIS 88
Arachidonic acid and its metabolites prostaglandin 1 and 2 increase intracellular calcium in cultured human osteoblast-like MG63 cells. 87
Protein diet and hypercalciuria 87
ROLE OF GLYCOSAMINOGLYCANS IN DIABETIC NEPHROPATHY 87
Abnormal erythrocyte and renal frusemide-sensitive sodium transport in idiopathic calcium nephrolithiasis. 87
EFFECT OF HEPARIN TREATMENT ON GLOMERULAR COLLAGEN-IV-ALPHA-1 AND TGF-BETA-1 EXPRESSION AND DEPOSITION IN DIABETIC RATS 86
Abnormal arachidonic acid content of membrane phospholipids - the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis 86
Isolation and properties of a protein kinase from rat liver microsomes. 86
Cardiovascular risk factors, smoking and kidney function 85
Renal structure incaucasian noninsulindependent diabetic patients. 85
Specific effect of arachidonic acid on inducible nitric oxide synthase mRNA expression in human osteoblastic cells 84
Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes 84
Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression 84
Von Willebrand factor abnormalities in IgA nephropathy. 81
ERYTHROCYTE URATE SELF-EXCHANGE IN IDIOPATHIC CALCIUM NEPHROLITHIASIS 81
ERYTHROCYTE URATE SELF-EXCHANGE IN IDIOPATHIC CALCIUM NEPHROLITHIASIS 80
Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. 78
MOLECULAR PATHOGENESIS OF MEMBRANOUS NEPHROPATHY 78
Growth factors and the kidney in diabetes mellitus. 78
Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. 77
Vascular endothelial growth factor expression in microdissected glomeruli of type 2 diabetic patients. 76
Treatment with glycosaminoglycans of renal diseases related problems. 76
Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis 76
Erythrocyte membrane protein phosphorylation in urolithiasis. 76
Use of glycosaminoglycans to increase efficiency long-term continuous peritoneal dialysis. 75
Mechanism of oxalate cellular transport in idiopathic calcium nephrolithiasis 74
Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients 74
Calcium nephrolithiasis - A systemic disease 73
Patterns of renal injury in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. 73
EFFECT OF HEPARIN TREATMENT ON GLOMERULAR-ALPHA-1-(IV)-COLLAGEN AND TGF-BETA-1 EXPRESSION AND DEPOSITION IN DIABETIC RATS 73
Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. 72
Renal function in the elderly: is the decline inevitable? 70
Diagnostic and therapeutic approach in patients with urinary calculi 70
Molecular biology of diabetic glomerulosclerosis 70
Genetic and dietary factors in idiopathic calcium nephrolithiasis. What do we have what do we need? 69
Altered Red-blood-cell Membrane-protein Phosphorylation In Idiopathic Calcium-oxalate Nephrolithiasis 69
Experimental peritoneal fibrosis: Favorable effects of glycosaminoglycans (GAGS) 68
Dietary fatty acid supplementation modulates the urinary excretion of calcium and oxalate in the rat. Insight into calcium lithogenesis 68
Oral glycosaminoglycans (GAGs) ameliorate peritoneal transport in CAPD patients. 68
TGF-beta 1 renal overexpression in diabetic rats and in high glucose mesangial cell cultures: Inhibition by heparinoids. 67
Dietary manipulation of delta-6-desaturase modifies phospholipid arachidonic acid levels and the urinary excretion of calcium and oxalate in the rat: insorgence of calcium lithogenesis 67
Ultrastructural measures of glomerular extracellular matrix accumulation in non-proteinuric type 2 diabetic patients. 66
Renal impairment in chronic cigarette smokers. 66
IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS - A CELLULAR-DISEASE 65
High urinary excretion of glycosaminoglycans: a possible marker of glomeular involvement in diabetes. 64
ANOMALOUS ARACHIDONIC-ACID METABOLISM IN IDIOPATHIC CALCIUM NEPHROLITHIASIS 64
EPA and DHA suppress AngII- and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. 63
Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinoger and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA) 63
Arachidonic acid influences intracellular calcium handling in human osteoblasts 63
Specific modulatory effect of arachidonic acid on bone cytokine mRNA expression 62
Fatty acids and idiopathic calcium nephrolithiasis 61
Nephrolithiasis - Diagnosis and treatment 60
Evidence of a link between erythrocyte band 3 phosphorylation and anion transport in patients with 'idiopathic' calcium oxalate nephrolithiasis. 60
Heparin reduces the glomerular infiltration by macrophages and modulates macrophage TGF beta and latent TGF beta binding protein synthesis in chronic puromycin glomerulosclerosis 60
Nutrition and calcium nephrolithiasis: The lipid hypothesis 59
Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalte nephrolithiasis. 59
IS HYPERPROSTAGLANDINURIA A PRIMITIVE PHENOMENON IN IDIOPATHIC CALCIUM NEPHROLITHIASIS 57
Favorable Effect of Glycosaminoglycans On Cellular and Urinary Abnormalities In Idiopathic Calcium-oxalate Nephrolithiasis 57
Totale 8.659
Categoria #
all - tutte 39.107
article - articoli 34.179
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 157
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.164
Totale 75.607


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.305 0 0 0 0 167 183 139 229 154 211 101 121
2020/20211.435 36 149 19 125 51 186 36 134 255 80 205 159
2021/20221.639 20 255 90 162 112 85 22 168 114 24 193 394
2022/20231.567 364 141 10 167 314 246 1 89 154 6 52 23
2023/2024630 26 82 64 48 34 40 21 123 12 3 91 86
2024/2025904 4 220 199 108 373 0 0 0 0 0 0 0
Totale 11.711